243 filings
8-K
DBVT
DBV Technologies
17 May 24
DBV Technologies Announces Plan to Implement ADS Ratio Change
4:38pm
8-K
DBVT
DBV Technologies
16 May 24
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
DBVT
DBV Technologies
7 May 24
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
4:39pm
8-K
DBVT
DBV Technologies
8 Mar 24
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
4:05pm
8-K
DBVT
DBV Technologies
7 Mar 24
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
5:17pm
8-K
lrw38xfhprml6
22 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:05am
8-K
blyw3m
9 Nov 23
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
4:52pm
8-K/A
upru tn29r2
6 Nov 23
Departure of Directors or Certain Officers
4:01pm
8-K/A
x8rj81
2 Nov 23
Departure of Directors or Certain Officers
8:00am
8-K
vme9pczfue 25u
31 Oct 23
Termination of a Material Definitive Agreement
4:54pm
8-K
6vbd2k
16 Oct 23
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
4:28pm
8-K
hjlb21ydcr u3x6h3k
31 Jul 23
Results of Operations and Financial Condition
5:20pm
8-K
c1ds0dmruj4602vy
11 May 23
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
8:27am
8-K
bn4uzx9d42mo1ffau9
4 May 23
DBV Technologies Reports First Quarter 2023 Financial Results
4:43pm
8-K
lxb7e r14pov
19 Apr 23
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
8:47pm
8-K
vhr9lcyh3kqv5tn
13 Apr 23
Submission of Matters to a Vote of Security Holders
8:01am
8-K
lfr 4yh9w
10 Mar 23
Regulation FD Disclosure
5:59pm
8-K
3722s 2rzz8e2zlh5ez
7 Mar 23
DBV Technologies Announces First Patient
5:09pm
8-K
2zgpv 9p4x1bw8
2 Mar 23
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
6:29pm
8-K
nife82mbtpa4kj5
23 Dec 22
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
9:59am